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Background and introduction
Mechanisms and sites of activity of zoledronic acid
Bisphosphonates localize to bone by mimicking pyro-
phosphate and binding to hydroxyapatite in mineralized 
bone. Zoledronic acid (ZA) is the most potent nitrogen-
containing bisphosphonate, and the majority of research 
studies and clinical trials have used ZA, which is the 
focus of this review.
After injection of a single dose of ZA its activity can be 
detected in bone 3  years later [1], but ZA plasma 
concentrations fall by 99% within 24 hours. ZA injection 
results in milli molar concentrations in bone, and at this 
high concen tration ZA is directly toxic to osteoclasts and 
limits bone turnover and skeletal-related events arising 
from bone-metastatic cancer.
ZA blocks protein isoprenylation, a key step in many 
survival and proliferation pathways. ZA inhibits farnesyl 
diphosphonate synthase and, to a lesser degree, geranyl-
geranylpyrophosphate synthase, both vital enzymes in 
the mevalonate pathway involved in biosynthesis of 
cholesterol. Th ese enzymes lead to prenylation and activa-
tion of key regulatory proteins, including farnesy lation of 
Ras family proteins and geranylgeranylation of Rho 
family proteins. Disruption of Ras undermines intra-
cellular vesicular transport and bone-resorptive capa bili-
ties of osteoclasts, ultimately leading to cell death. 
Although these eﬀ ects of ZA have been most extensively 
studied in the bone microenvironment, ZA also has 
bone-extrinsic eﬀ ects, including modulation of cell migra-
tion, angiogenesis, and immunity. Direct induction of 
cancer cell death by ZA has also been noted in vitro, 
albeit at high ZA concentrations that are not achieved 
outside bone. Th ese eﬀ ects of ZA and other bisphos-
phonates have been extensively reviewed [2].
Clinical effi  cacy of zoledronic acid, and potential hormone-
dependent eff ects on breast cancer cells
In patients, ZA has been eﬀ ective against both lytic and 
blastic bone disease, reducing bone symptoms and 
skeletal-related events in bone-metastatic prostate 
cancer, bladder cancer, hepatocellular cancer, breast 
cancer, lung cancer, and multiple myeloma [3]. Th e ability 
of ZA to decrease the cancer burden in bone is under-
standable, given its high concentration and long half-life 
in the bone environment. For instance, liberation of ZA 
from hydroxyapetite during bone turnover could allow 
accumulation of the high ZA concentrations required in 
vitro for direct anti-cancer cell eﬀ ects. More surprising 
have been results from recent clinical studies identifying 
anti-cancer eﬃ  cacy of ZA beyond the setting of bone 
metastases, leading to increased disease-free survival 
(DFS).
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however, there was a lack of an anti-cancer eff ect 
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ZA activity in premenopausal women compared with 
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In the Austrian Breast & Colorectal Cancer Study 
Group 12 (ABCSG12) study, 3  years of ZA added to 
endocrine therapy increased the DFS of premenopausal 
women with stage I/II breast cancer compared with 
endo crine therapy alone. All of the premenopausal 
women in the ABCSG12 trial received luteinizing 
hormone-releasing hormone agonist goserelin to 
suppress production of estrogen and progesterone. 
Production or function of estrogen was further inhibited 
by anastrozole or by tamoxifen. Th e study demonstrated 
a 36% reduction overall in the relative risk of disease 
progression among those patients taking ZA. Th e 
increased DFS was sustained after treatment cessation to 
82 months [4]. Notably, the ABCSG12 trial demonstrated 
that ZA reduced both intra-osseous and extra-osseous 
breast cancer recurrence and locoregional recurrences in 
these premenopausal women on hormone suppression.
In contrast, the Adjuvant Zoledronic Acid to Reduce 
Recurrence (AZURE) trial indicated that addition of ZA 
to standard therapy did not prolong DFS in women with 
stage II/III breast cancer [5]. Th e AZURE study enrolled 
2,259 premenopausal or perimenopausal women and 
1,101 postmenopausal women, nearly all of whom received 
chemotherapy, and randomized them to adjuvant ZA 
treatment or placebo. ZA did not improve the overall 
survival or DFS of the entire cohort, but a prespeciﬁ ed 
subgroup analysis in the AZURE study indicated that 
postmenopausal women – but not premenopausal 
women – treated with ZA showed an increased DFS of a 
magnitude comparable with that observed in the 
ABGCS12 trial [5]. ZA was eﬀ ective in preventing new 
secondary primary tumors and locoregional and non-
skeletal distant recurrences in postmenopausal women in 
the AZURE trial.
Although not the primary endpoint, a DFS beneﬁ t of 
ZA treatment in postmenopausal women has also been 
supported by trials in which postmenopausal women 
with early-stage hormone-responsive breast cancer were 
treated with the aromatase inhibitor letrozole and were 
randomized to either immediate or delayed ZA (the ZO-
Fast, Z-Fast, E-ZO-Fast and N03CC trials). Delayed ZA 
therapy was triggered by nontraumatic fracture or cross-
ing a bone loss threshold. Th e results not only 
demonstrated improved bone mineral density (the 
primary endpoint) with immediate ZA treatment, but 
showed a beneﬁ t for DFS – in the ZO-Fast trial at 
48 months [6] and in the Z-Fast trial at 12 to 48 months 
but not at 5 years [7] (the two other similar trials (E-ZO-
Fast and N03CC) had insuﬃ  cient data to evaluate 
recurrence at 12 months [8,9]). Additional information is 
presented in Table 1.
Collectively, these trials have led to several conclusions 
and potential interpretations. First, there is evidence of 
an anti-cancer eﬀ ect of ZA that is not limited to bone. 
Second, ZA opposes breast cancer recurrence in sex-
hormone-poor environments (that is, goserelin plus anti-
estrogens or in postmenopausal women). Although the 
ABCSG12 and AZURE trials diﬀ er in enrollment criteria 
and the extent of adjuvant chemotherapy usage, the 
beneﬁ t of ZA in premenopausal women in the ABCSG12 
trial and not in the AZURE trial has been interpreted as 
an inhibitory eﬀ ect of sex hormones on the ability of ZA 
to augment DFS [5]. Th ird, the lack of anti-cancer 
eﬀ ectiveness of ZA in premenopausal women could not 
be rescued by tamoxifen alone, given that 74% of subjects 
in each arm of the AZURE trial received tamoxifen plus 
chemotherapy [5] (R Coleman, personal communication). 
Opposition of ZA improvement of DFS could therefore 
be mediated by tamoxifen-insensitive estrogen receptor 
(ER) activity or through the activity of other, goserelin-
sensitive, hormones. Finally, results from the AZURE 
trial showed that premenopausal women responded 
poorly to ZA – independent of the ER status of the tumor. 
ZA resistance in premenopausal women may there fore 
not arise from estrogen or progesterone signal ing within 
the cancer cells themselves, but rather from sex hormone 
eﬀ ects on the premenopausal micro environment.
In this review we consider how these interpretations 
could be informed by preclinical in vitro and in vivo 
studies of ZA activity, focusing on the possible endocrine-
dependent eﬀ ects of ZA activity. In the AZURE trial, 
premenopausal women with either ER-positive or ER-
negative tumors responded less well to ZA than did 
postmenopausal women [5]. Th is ﬁ nding indicates that 
sex hormones did not solely antagonize ZA by acting on 
cancer cells but through hormonal manipulation of 
stroma or the tumor microenvironment, which we will 
discuss here. Although a number of hormone receptor 
pathways could be involved in the diﬀ erential ZA 
responses, we will focus on estrogen, and only brieﬂ y 
discuss other hormones such as progesterone and 
inhibin.
Eff ects of zoledronic acid in bone
ZA, mimicking pyrophosphate, binds to hydroxyapatite 
in mineralized bone, and is directly toxic to osteoclasts – 
it limits bone turnover and skeletal-related events arising 
from bone-metastatic cancer. By inhibiting osteoclast-
mediated bone resorption, ZA lowers bone marrow 
calcium and impedes the liberation of growth factors 
from the bone matrix that contribute to the vicious cycle 
of metastasis growth and bone breakdown. Th ere are 
some data suggesting that bisphosphonates can have 
additional, osteoclast-independent eﬀ ects. For example, 
ZA was shown to be eﬀ ective against bone tumors in 
mice with nonfunctional osteoclasts [10]. However, ZA’s 
primary eﬀ ect on osteoclasts is supported by data in 
patients with advanced breast cancer showing that 
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ZA-treated breast cancer patients in whom ZA rapidly 
normalized bone turnover (manifested by N-telopeptide 
of type I collagen) had longer event-free survival and 
overall survival than those with continued high turnover 
[11].
In addition to the inhibition of osteoclast activity, ZA 
was shown to have many other activities within bone 
itself that could explain its ability to prevent recurrence 
of breast cancer. ZA downregulates adhesion molecules 
on bone marrow stromal cells and inhibits tumor cell 
adhesion to the bone matrix whether the tumor cells or 
the matrix are treated with bisphosphonate [12]. ZA also 
promotes osteoblast maturation and production of the 
rank ligand antagonist osteoprotegerin, an inhibitor of 
osteolysis [13]. Moreover, ZA has been shown to inhibit 
stromal IL-6 secretion and matrix metallo proteinase-1 
production, eﬀ ects that could block tumor growth in 
bone or at other sites.
Th ere is increasing evidence that ZA could aﬀ ect 
survival of disseminated tumor cells, whose prevalence 
predicts local and distant relapse [14]. Both neoadjuvant 
and post chemotherapy administration of ZA (and other 
bisphos phonates) have been shown to decrease 
disseminated tumor cells in marrow compared with 
pretreatment levels [15,16], lowering the risk of 
metastatic spread from micrometastases. Th is occurrence 
could represent an anti-cancer eﬀ ect. Interestingly, 
osteoclasts and osteoblasts have been implicated in the 
maintenance of dormant leukemic clones in the marrow 
[17], which may also be the case for breast cancer. 
Moreover, breast tumor cell viability in the endosteal 
niche has been shown to involve heterotypic notch/
jagged interactions with osteoblasts similar to those used 
to regulate hematopoietic stem cell numbers [18,19]. 
ZA-mediated shifts in osteoclast and osteoblast function 
may therefore lead to changes in the microenvironment 
that undermine support for disseminated cancer cells.
Estrogen actions in bone as a modulator of zoledronic acid 
eff ectiveness
As described above, the clinical data point towards a role 
for low-estrogen environments in high ZA eﬃ  cacy. A 
possible caveat is the clinical observation that most of the 
premenopausal women in the AZURE trial who reaped 
no beneﬁ t from ZA were receiving tamoxifen. Con-
ceivably, tamoxifen did not adequately block estrogen 
signaling that undermined ZA (discussed below); 
alternatively, the critical action of estrogen impairing the 
ZA anti-tumor eﬀ ect occurred at a site where tamoxifen 
functioned as an agonist (for example, bone). Like 
estrogen, tamoxifen opposes bone turnover (albeit to a 
lesser degree [20]), and thus suppression of bone turn-
over by tamoxifen or estrogen may limit the magnitude of 
beneﬁ t accruing from ZA treatment because ZA has a 
greater survival beneﬁ t in patients with bone metastases 
with high basal levels of bone turnover [21].
Studies have not yet uncovered a mechanistic process 
that would link estrogen-suppressed bone turnover and 
decreased DFS among ZA-treated women. Bone meta-
stases in premenopausal women may be less dependent 
on calcium and on cytokines liberated from bone and the 
matrix by osteoclasts than those in postmenopausal 
women. Th is could render the premenopausal women 
less sensitive to downstream eﬀ ects of ZA that lower 
local calcium and cytokine levels. Another possibility is 
that the bone microenvironment in estrogen-exposed 
women better supports the survival and expansion of 
disseminated tumor cells in the endosteal niche. Th is idea 
Table 1. Zoledronic acid trials and disease-free survival
Trial Hormonal status ZA/hormonal intervention Eff ect of ZA
Z-Fast [7] (n = 602) Postmenopausal women Immediate versus delayed ZA plus 
adjuvant letrazole
Decreased recurrence at 12 to 48 months, not 
at 60 months
ZO-Fast [6] (n = 868) Postmenopausal women Immediate versus delayed ZA plus 
adjuvant letrazole
Reduction in DFS (HR = 0.59) at 36 and 
48 months. Disease recurrence reduced at 
bone and at nonbone sites
ABCSG12 [4] (n = 1,803) Premenopausal ER/PR-positive 
stage 1/2 breast cancer 
Phase 3 2×2 trial, goserelin ± 
tamoxifen or anastrozole ± ZA
Reduction in DFS (HR = 0.68) at 48 and 
62 months. Disease recurrence reduced at 
bone and at nonbone sites
AZURE [5] (n = 3,360) Premenopausal and 
postmenopausal stage 2/3 breast 
cancer 
Phase 3 trial, standard adjuvant 
systemic therapy including 
hormonal ± ZA
Lack of eff ect on invasive DFS. Subgroup 
analysis indicated benefi t in women ≥5 years 
postmenopausal (HR = 0.75)
AZURE subgroup [72] (n = 205) Premenopausal and 
postmenopausal stage 2/3 breast 
cancer 
Neoadjuvant chemotherapy ± ZA Reduced residual invasive tumor size by 44%
ABCSG12, Austrian Breast & Colorectal Cancer Study Group 12; AZURE, Adjuvant Zoledronic Acid to Reduce Recurrence; DFS, disease-free survival; ER, estrogen 
receptor; HR, hazard ratio; PR, progesterone receptor; ZA, zoledronic acid.
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is supported by the ﬁ ndings that estrogen increases the 
number and activity of endosteal osteoblasts [22], which 
are critical mediators of stem cell dormancy and survival 
[23]; estrogen may thereby impede the ability of ZA to 
decrease disseminated tumor cells. To better understand 
whether estrogen and ZA interact at the level of 
dormancy, it will be important to measure the eﬀ ect of 
ZA on the ability of estrogen-replete and estrogen-
deprived endosteum to support cancer.
Estrogen deﬁ ciency, on the contrary, might bolster ZA 
action. Estrogen deﬁ ciency has been linked to increased 
expression of IL-1 (reviewed in [24]). Th ere is early but 
intriguing evidence that could link IL-1α to the transition 
from latency to clinical disease. IL-1 has been shown to 
mobilize hematopoietic stem cells from the stem/
progenitor niche. IL-1 is a TNFα target, and a recent 
report demonstrated that TNFα-dependent factors have 
converted latent breast cancer to symptomatic disease in 
a mouse model [25]. Both of these factors may activate 
cancer cells in the bone niche [25]. Conceivably, estrogen 
deﬁ ciency could thereby unmask latent disseminated 
breast cancer cells in the bone environment, making 
them susceptible to death from high local ZA 
concentrations.
Inhibin activity in bone – role in zoledronic acid effi  cacy?
Hormones other than steroids could engender a tumor 
microenvironment that is less responsive to ZA. Th e 
gonadal peptides inhibin A and inhibin B, which are 
highly expressed in premenopausal women but are 
blocked in postmenopausal or ovarian-suppressed pre-
meno pausal women, appear to sustain bone mass. Loss of 
inhibin has previously been suggested as a factor in the 
anti-cancer eﬀ ect of ZA in postmenopausal women [26]. 
Brieﬂ y, decreased inhibin levels in perimenopause are 
associated with derepression of follicle-stimulating 
hormone production, deactivation of activins, and bone 
loss (reviewed in [27]). In both premenopausal women 
and postmenopausal women, inhibin levels are inversely 
correlated with bone turnover, independent of estrogen 
expression. Th e inhibin-poor environment of postmeno-
pausal women (as in the AZURE, Z-FAST and ZO-FAST 
trials) or ovarian-suppressed women (as in the ABCSG12 
trial) can therefore support the high bone turnover 
condition in which ZA is most eﬀ ective (as discussed 
above in the context of estrogen deprivation). One caveat 
is that inhibin may not be eliminated from the tumor 
setting by goserelin or menopause because of breast 
cancer cell expression of inhibin A (in ductal carcinoma 
in situ) and inhibin B (in primary tumors and metastases) 
subunits [28]. Gonadal-independent expres sion of 
inhibins in the local breast cancer micro environment 
could thus potentially oﬀ set the signiﬁ cance of endocrine 
suppression of inhibins. Clearly, additional studies are 
needed to understand a potential role for the inhibins in 
ZA activity.
Angiogenesis
Zoledronic acid eff ects on angiogenesis
Decreased tumor angiogenesis – associated with decreased 
endothelial proliferation in response to vascular 
endothelial growth factor (VEGF) – was observed in ZA-
treated mice, and ZA-treated patients have decreased 
circulating levels of the pro-angiogenic molecule VEGF 
[29]. Indirect eﬀ ects of ZA on angiogenesis arise from 
eﬀ ects of ZA on macrophage polarization leading to a 
decrease in tumor-associated macrophages that promote 
vascularization and support circulating VEGF levels [30].
Candidate estrogen eff ects opposite to zoledronic acid on 
angiogenesis
Whereas ZA treatment decreased serum VEGF in vitro 
and in vivo, estrogen is known to cause transient 
upregulation of VEGF production in noncancerous cells 
[31], and to cause sustained low-level VEGF expression 
by cancer cells themselves in vitro and in vivo [32]. In 
mouse tumors comprised of species-speciﬁ c breast 
cancer and stromal cells, Saarinen and colleagues demon-
strated estrogen induction of the angiogenic cytokines in 
the stroma, implicating these as mediators of host angio-
genesis [33]. In addition, estrogen has been reported to 
upregulate α5-integrin [34] whereas ZA down regulates 
these integrins and adhesion in endothelial cells [35].
Immunity
Eff ects of zoledronic acid on macrophage polarization
While tumor inﬁ ltration by macrophages is common, the 
function of these macrophages can either be immune 
suppressive and tumor promoting (M2 phenotype) or be 
tumor suppressive (M1 phenotype). ZA seems to 
promote the tumor-suppressive phenotype; for example, 
it promoted a switch of pro-tumorigenic M2 macro-
phages in co-culture with prostate cancer cells to M1 
polarization [36]. In an erb-B2 mouse model, Coscia and 
colleagues have shown that the ability of ZA to inhibit 
cancer was correlated with its ability to impair the 
recruitment of macrophages into tumors and to support 
M1 polarization of macrophages in tumors as manifested 
by decreased IL-10 and increased IFNγ production [30]. 
Th e contribution of macrophages to the anti-cancer eﬀ ect 
of bisphos phonates has been reviewed recently [37].
Candidate estrogen and progesterone eff ects opposite to 
zoledronic acid on macrophage polarization
Estrogen has been posited as supportive of the M2 
phenotype [38], consistent with reports that it down-
regulates the M1-promoting cytokine migration inhibi-
tory factor [39]. Like estrogen, progesterone has been 
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found to promote alternative activation of macrophages 
[40]. Whereas ZA repolarizes macrophages to nitric-
oxide-producing M1 macrophages, progesterone has 
been found to down regulate nitric oxide synthase activity 
in bone marrow macrophages [41]. Additional studies are 
necessary to fully understand the potential interaction 
between sex steroids, eﬀ ect of ZA, and macrophage 
polarization.
Zoledronic acid eff ects on γδ T cells and natural killer cells
ZA increases the immunogenicity of cancer cells by 
increasing presentation of the prenyl phosphate antigens 
isoprenyl pyrophosphate and ApppI (resulting from 
isoprenyl pyrophosphate–AMP binding) on the cell 
surface [42]. Prenyl phosphate antigens promoted anti-
tumor immunity by activating the tumor-suppressive γδ 
T-cell subset. γδ T-cell expansion and activation has been 
conﬁ rmed in cancer patients after ZA administration 
[43], leading to a phase I trial of ZA plus IL-2 to augment 
γδ T-cell activity in women with late-phase breast cancer. 
In addition to promoting IFNγ production by γδ T cells, 
ZA has been shown to induce IFNγ production by 
natural killer (NK) cells [44]. Anti-cancer eﬀ ects of ZA 
have been eliminated in a mouse breast cancer model 
when IFNγ was knocked out [30]. Th e relative import-
ance of macrophage-generated, NK cell-generated or γδ 
T-cell-generated IFNγ in ZA eﬀ ectiveness against cancer 
is unknown.
Candidate progesterone and estrogen eff ects opposing 
zoledronic acid on γδ T cells or NK cells
Although limited data are available, there is preclinical 
evidence that estrogen can increase the growth of ER-
negative tumors in immunodeﬁ cient mice by suppressing 
NK-cell cytotoxicity [45]. Estrogen has also been shown 
to increase levels of granzyme B inhibitor, leading to 
resistance of cancer cells to killing by NK cells [46]. Th ere 
is also increasing evidence for progesterone playing a role 
in the regulation of γδ T cells. While expression of 
progesterone receptors on lymphocytes (particularly γδ 
T cells) has been studied primarily in pregnancy, signal 
transduction through progesterone receptors has 
recently been reported in peripheral T cells [47]. It has 
been hypothesized that responsive T cells could produce 
progesterone-induced blocking factor, an inhibitor of NK 
cell function [48]. Although far from established, whether 
progesterone or other sex hormones could oppose the 
activation of NK cells by ZA would be interesting.
Cell migration and invasion
Inhibition of cell migration by zoledronic acid
ZA decreases the migration of mesenchymal stem cells in 
vitro and lowers their production of CCL5 chemokine 
[49]. Mesenchymal stem cells migrate from bone marrow 
to the primary tumor, where they are induced to produce 
CCL5 that promotes breast cancer migration and meta-
stases [50] – suggesting that anti-tumor eﬀ ects of ZA 
could be mediated in part through suppression of 
mesenchymal stem cell movement and activity. ZA also 
decreases breast cancer invasion [51] and endothelial cell 
migration [52].
Promotion of migration by estrogen
In contrast to ZA, estrogen has been noted to increase 
endothelial cell migration [53]. Estrogen can directly 
increase cancer cell migration and also can increase the 
ability of mesenchymal stem cells to promote the migra-
tion of ER-positive MCF7 breast cancer cells [54]. Th ese 
pro-migratory activities would probably be antagonized 
by ZA, however, because the migration is supported by 
prenylation of Rho and Rac [55].
Growth factor milieu
Zoledronic acid eff ects on pro-tumorigenic growth factor 
signaling
ZA inhibition of Ras prenylation is compatible with 
suppression of transduction by proliferative cytokines 
and mitogens. ZA has been reported to alter breast 
cancer cell responsiveness to growth factors in vitro. 
Fromigue and colleagues demonstrated that 1 μM ZA 
blocked the ability of insulin-like growth factor-1 and 
insulin-like growth factor-2 to support the survival of 
breast cancer cells cultured in serum-free medium [56]. 
Th is blocking could be critical since insulin-like growth 
factors are among the cytokines that are upregulated in 
the metastatic milieu. ZA has also been reported to 
inhibit the production of hepatocyte growth factor by 
macrophages [57]; given that hepatocyte growth factor 
supports breast cancer cell invasion, chemoresistance 
and DNA repair capability, this process could also be 
involved in modulation of the extra-osseous anti-tumor 
activity of ZA.
Candidate estrogen eff ects opposite to zoledronic acid on 
pro-tumorigenic growth factors
Th ere is a well-established crosstalk between estrogen 
signaling and growth factor pathways, including reports 
on estrogen-mediated induction of a number of growth 
factors in peritumoral stroma. For example, estrogen has 
been noted to induce hepatocyte growth factor secretion 
by macrophages [58] and mammary ﬁ broblasts [59]. 
Hepatocyte growth factor signaling through the c-met 
receptor activates mitogen-activated protein kinases 
inde pen dently of Ras, and could represent a rescue 
pathway around Ras inactivation by ZA [60].
Th e Kuperwasser group provides another example of 
indirect tumor-promoting eﬀ ects of hormones acting on 
stroma or marrow rather than on cancer cells themselves. 
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Brieﬂ y, they showed that estrogen can promote growth of 
ER-negative tumors in a stromal-dependent fashion. 
Interestingly, enhanced growth of ER-negative breast 
cancer was transferable with bone marrow from 
estrogen-treated mice [61]. Th e relevance of these studies 
to human disease is still somewhat unclear given that the 
beneﬁ t of hormonal blockade as monotherapy clearly 
depends on the ER expression in the patient’s tumor cells.
It is conceivable that cancer recurs in premenopausal 
women taking ZA because of enhanced formation of 
peripheral metastatic niches. Th e establishment of the 
peripheral metastatic niche has been linked to pro-
tumorigenic conversion of stroma resulting from 
granulin-producing bone marrow cells [62]. Estrogen has 
been shown to upregulate pro-granulin expression in 
tumor cells and nontumor cells [63]. Conceivably, 
estrogen could increase granulin levels in migrating 
marrow cells to increase visceral metastasis. Further 
studies to determine the eﬀ ect of ZA and sex hormones 
on the mobilization and function of granulin-expressing 
cells could be informative.
Resistance to zoledronic acid
Th ere are limited reports of ZA-resistant cell lines arising 
from long-term low-dose exposure to ZA. An MCF-7 cell 
line resistant to ZA exhibited cross-resistance to several 
chemotherapeutic agents, and expressed an increased 
Bcl2/Bax ratio and increased ABC transporters BRCP 
and LRP [64]. Analysis of ZA-resistant osteosarcoma 
cells arising from culture in low-dose ZA disclosed a 
farnesyl diphosphate synthase-dependent resistance 
mechanism in one instance and a heat shock protein-27-
dependent mecha nism in the other [65,66]. Th ese few 
reports suggest that intrinsic cancer cell resistance to ZA 
may be multi factorial. Whether extrinsic resistance to 
ZA arises through restoration of pro-tumorigenic para-
crine or juxtacrine factors in the tumor microenviron-
ment is unknown.
Estrogen modulation of hsp27
Estrogen has been shown to transcriptionally upregulate 
the hsp27 chaperone in both cancer cells [67] and 
osteoblasts [68], bolstering cell survival in the presence of 
apoptotic stimuli. Given the ﬁ nding that hsp27 was 
required for acquired resistance of osteosarcoma cells to 
ZA [66], it is possible that heightened hsp27 in pre-
menopausal women contributes to ZA resistance among 
those not treated with anti-endocrine therapy.
Estrogen and the prenylation pathway
It is worth considering whether estrogenic environments 
directly interfere with downstream signals of ZA. Dalenc 
and colleagues showed that neither tamoxifen nor the 
pure anti-estrogen ICI182780 (fulvestrant) aﬀ ected 
farnesylation [69]. Th e ability of ZA to interfere with 
prenylation is therefore unlikely to diﬀ er in estrogen-rich 
and estrogen-poor environments.
Chemoresistance and integrin-5
No datasets that proﬁ le ZA-sensitive and ZA-resistant 
stroma or tumors are currently available to analyze for 
enrichment of estrogen-related pathways linked to ZA 
resistance. Although knowledge of estrogen-induced 
changes in stroma that cause chemoresistance is limited, 
much is known about the stromal role in supporting 
cancer resistance to chemotherapy. Stromal gene 
signatures have been identiﬁ ed that predict resistance to 
neoadjuvant chemotherapy for breast cancer [70]. To 
interrogate this signature for estrogen-directed trans-
cripts, we conducted gene ontogeny and pathway analysis 
using GeneGo (Metacore, Inc., Philadelphia, PA, USA) 
software (RAS, unpublished obser vations). Our analysis 
indicated the strongest association of this resistance 
signature with signaling through α5-integrins (Z score = 
144, P = 10–84). As noted earlier, integrin 5 is down-
regulated by ZA and transcriptionally upregulated by 
estrogen.
Conclusion and questions for the future
While the mechanism of action is not yet known, 
adjuvant treatment with ZA does appear to improve DFS 
and overall survival in early-stage breast cancer patients 
with ovarian suppression. ZA eﬀ ectiveness as an anti-
tumor (as well as anti-osteolytic) agent could lead to 
broader incorporation of ZA (and next-generation 
bisphosphonates) in clinical practice. Optimal use of ZA 
in cancer will depend on identiﬁ cation of patient sub-
groups most likely to beneﬁ t, on delineation of mecha-
nisms of ZA anti-tumor action that are consistent with 
its pharmacokinetics, and on identiﬁ cation of agents that 
can be optimally combined with ZA and/or can overcome 
resistance of cancers to ZA action. Progress will depend 
on correlated preclinical and clinical studies that uncover 
whether previously reported eﬀ ects of ZA (for example, 
on γδ T-cell expansion, on circulating VEGF) diﬀ er as a 
function of hormonal status.
We note that there is support in the literature for 
complex and multifactorial interaction between ZA and 
hormones both within and outside the bone environ-
ment. Estrogen, acting through osteoblasts, could support 
a dormant tumor cell niche in bone, enabling dissemi-
nated cells to survive high intra-osseous ZA levels. ZA 
and estrogen could have antagonistic eﬀ ects on cytokine 
stimulation of angiogenesis, on tumor-promoting or 
suppressing activation of macrophages, or on the 
mobilization and function of NK cells acting on tumors. 
Th ese examples of candidate ZA/hormone interactions 
are summarized in Figure 1.
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One clinically relevant question is whether hormone-
sensitive anti-cancer eﬀ ects are speciﬁ c to ZA or are a 
class eﬀ ect or a general eﬀ ect with bisphosphonates. Th e 
recently published NSABP-34 trial assigned women with 
operable primary breast cancer to adjuvant placebo or to 
the non-nitrogen-containing bisphosphonate clodronate 
for 3 years. Similar to the AZURE trial, no beneﬁ t in DFS 
or overall survival was detected in the clodronate arm, 
whereas treatment with clodronate increased DFS and 
the metastasis free-interval in the subset of women aged 
over 50 [71]. Clodronate lacks the ability of ZA to inhibit 
the mevalo nate pathway, so this trial could highlight a 
diﬀ erent, common, endocrine-sensitive eﬀ ect of these 
bisphospho nates.
Other clinically relevant questions include the follow-
ing. Do other compounds that suppress bone turnover, 
such as denosumab, have this same eﬀ ect, despite 
suppressing bone via a diﬀ erent mechanism? Are there 
patient-speciﬁ c factors other than hormonal status that 
predict beneﬁ t from ZA? Do the beneﬁ ts of adding ZA to 
endocrine therapy in postmenopausal women equal the 
beneﬁ ts of adding chemotherapy for these women? Is 
there an additive or synergistic eﬀ ect from ZA, endocrine 
therapy, and chemotherapy? Answers to these questions 
should help to integrate therapy with ZA into the 
standard of care for early-stage breast cancer.
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Figure 1. Potential sites of estrogen antagonism of zoledronic acid function. Bone-bound zoledronic acid (ZA) poisons osteoclasts and 
inhibits liberation of matrix-bound cytokines. Cytokines induced by stroma or macrophages are also inhibited by ZA but can be upregulated by 
estrogen. Estrogen also increases numbers of endosteal osteoblasts that can support disseminated tumor cells. Tumor cell migration to extra-
osseous sites could be suppressed by anti-angiogenic and anti-migratory eff ects of ZA, while estrogen support of angiogenesis could promote 
cancer cell proliferation and dissemination. At extra-osseous sites, estrogen and ZA are proposed to have opposing eff ects on macrophage 
polarization and natural killer (NK) activity as described in the text. ZA up to 1 mM intra-osseous and 1 μM extra-osseous concentrations. DTC, 
quiescent disseminated tumor cell; E2, estrogen; FGF, fi broblast growth factor; IGF, insulin-like growth factor; M1 or M2, macrophages polarized to 
M1 or M2, respectively; MMP1, matrix metalloproteinase-1; PDGF, platelet-derived growth factor; TGF, transforming growth factor; VEGF, vascular 
endothelial growth factor.
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